Targeted delivery of paclitaxel and doxorubicin to cancer xenografts via the nanoparticle of nano-diamino-tetrac


Sudha T., Bharali D. J. , Yalcin M. , Darwish N. H. E. , Coskun M. D. , Keating K. A. , ...More

INTERNATIONAL JOURNAL OF NANOMEDICINE, vol.12, pp.1305-1315, 2017 (Journal Indexed in SCI) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 12
  • Publication Date: 2017
  • Doi Number: 10.2147/ijn.s123742
  • Title of Journal : INTERNATIONAL JOURNAL OF NANOMEDICINE
  • Page Numbers: pp.1305-1315

Abstract

The tetraiodothyroacetic acid (tetrac) component of nano-diamino-tetrac (NDAT) is chemically bonded via a linker to a poly(lactic-co-glycolic acid) nanoparticle that can encapsulate anticancer drugs. Tetrac targets the plasma membrane of cancer cells at a receptor on the extracellular domain of integrin alpha v beta 3. In this study, we evaluate the efficiency of NDAT delivery of paclitaxel and doxorubicin to, respectively, pancreatic and breast cancer orthotopic nude mouse xenografts. Intra-tumoral drug concentrations were 5-fold (paclitaxel; P < 0.001) and 2.3-fold (doxorubicin; P < 0.01) higher than with conventional systemic drug administration. Tumor volume reductions reflected enhanced xenograft drug uptake. Cell viability was estimated by bioluminescent signaling in pancreatic tumors and confirmed an increased paclitaxel effect with drug delivery by NDAT. NDAT delivery of chemotherapy increases drug delivery to cancers and increases drug efficacy.